GLP-1 Medications and Addiction Medicine: What Is Known, What Is Not, and What Families Should Ask
The early signal is clinically interesting. It is not the same thing as proof.
This page is educational only and does not replace individualized medical advice, diagnosis, or treatment. Ratush Recovery is not an emergency service or crisis line. If there is immediate danger or a medical emergency, call 911 or go to the nearest emergency department. For mental health or substance-use crisis support, call or text 988.
GLP-1 medications are being studied for possible effects on craving, reward, alcohol use, and substance-use behavior, but they are not established addiction treatments. Families should distinguish early signals from clinical proof and should not use GLP-1 medications as a substitute for evidence-based addiction care or individualized medical evaluation.
What GLP-1 medications are
GLP-1 receptor agonists and related medications were developed around metabolic disease, including diabetes and weight management. Their effects include appetite, satiety, glucose regulation, and central reward-related pathways.
The question for addiction medicine is whether those reward-related effects may matter for craving or substance-use behavior in some patients.
Why addiction medicine is paying attention
Clinicians began hearing patient reports of quieter cravings while patients were taking GLP-1 medications for metabolic indications.
Those reports do not prove treatment efficacy, but they helped generate research into alcohol use, reward behavior, and other substance-use outcomes.
What is promising
The promising part is not a claim that these medications treat addiction. The promising part is that they may help researchers understand how appetite, reward, salience, craving, and compulsive behavior overlap biologically.
Early studies and clinical observations justify careful attention and further trials.
What remains uncertain
It remains uncertain which patients, which substances, which medications, which doses, which time frames, and which combinations of care may matter.
It is also unclear how benefits, side effects, psychiatric symptoms, nutritional status, and recovery engagement interact over time.
Why hype can be dangerous
Hype can lead patients to delay evidence-based treatment, stop medication for opioid or alcohol use disorder, or assume a metabolic medication can replace recovery structure.
That is not supported by current evidence and may be clinically dangerous.
Questions families should ask
Families should ask whether there is a metabolic indication, what evidence supports the proposed use, what established addiction treatments are also being considered, who is monitoring side effects, and how relapse risk will be handled if cravings change.
They should also ask whether the prescribing clinician is coordinating with the physician responsible for the addiction case.
When established addiction treatment should not be delayed
Treatment for opioid use disorder, alcohol withdrawal risk, severe psychiatric symptoms, overdose risk, suicidality, or medical instability should not be delayed because a family is interested in GLP-1 medications.
Evidence-based addiction care and emergency care remain the priority when risk is active.
Edward Ratush, MD is a board-certified psychiatrist and addiction medicine physician. Ratush Recovery is his concierge recovery medicine practice for selected patients and families when the proposed work is medically, legally, and logistically appropriate. Learn more on the physician profile, review selected media and commentary, read the writing index, or review the clinical scope and limitations.
Related reading
Clinical notes and references
These sources are included for educational context. They are not a substitute for patient-specific medical evaluation.
- Leggio et al.: GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders
- GLP-1 agonists and reward behaviour: systematic review
- Association between GLP-1 receptor agonist use and alcohol consumption: systematic review
- Once-weekly semaglutide in adults with alcohol use disorder: randomized clinical trial